Visannette-2 Dosage

What is the dose of your medication?
sponsored

Dosage of Visannette-2 in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

1 tab daily without any break, taken preferably at the same time each day with some liquid as needed. Tablets must be taken continuously without regard to vaginal bleeding. When a pack is finished the next one should be started without interruption.

Tablet-taking can be started on any day of the menstrual cycle.

There is no experience with Visannette-2 treatment >15 months in patients with endometriosis.

The efficacy of Visannette-2 may be reduced in the event of missed tablets, vomiting and/or diarrhea (if occurring within 3-4 hrs after tab taking). In the event of missed tablet(s), the woman should take 1 tab only, as soon as she remembers, and should then continue the next day to take the tab at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by 1 tablet.

Renal Impairment: There are no data suggesting the need for a dosage adjustment in patients with renal impairment.

Hepatic Impairment: Visannette-2 is contraindicated in patients with present or past severe hepatic disease.

Administration: For oral use.

Visannette-2 interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Visannette-2, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Effects of Other Drugs on Visannette-2: Individual Enzyme-Inducers or Inhibitors (CYP3A4): Progestogens including Visannette-2 are metabolized mainly by the cytochrome P-450 3A4 system (CYP3A4), located both in the intestinal mucosa and in the liver. Therefore, inducers or inhibitors of CYP3A4 may affect the progestogen drug metabolism.

An increased clearance of sex hormones due to enzyme induction may reduce the therapeutic effect of Visannette-2 and may result in undesirable effects eg, changes in the uterine bleeding profile.

A reduced clearance of sex hormones due to enzyme inhibition may increase the exposure to Visannette-2 and may result in undesirable effects.

Substances with Enzyme-Inducing Properties: Interactions can occur with drugs (eg, phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin, nevirapine and products containing St. John’s wort) that induce microsomal enzymes (eg, cytochrome P-450 enzymes) which can result in increased clearance of sex hormones.

Maximum enzyme induction is generally not seen for 2-3 weeks but may then be sustained for at least 4 weeks after the cessation of therapy.

The effect of the CYP3A4 inducer rifampicin was studied in healthy postmenopausal women. Co-administration of rifampicin with estradiol valerate/Visannette-2 tablets led to significant decreases in steady-state concentrations and systemic exposures of Visannette-2 and estradiol. The systemic exposure of Visannette-2 and estradiol at steady state, measured by AUC (0-24 hrs), were decreased by 83% and 44%, respectively.

Substances with Enzyme-Inhibiting Properties: Known CYP3A4 inhibitors like azole antifungals (eg, ketoconazole, itraconazole, fluconazole), cimetidine, verapamil, macrolides (eg, erythromycin, clarithromycin and roxithromycin), diltiazem, protease inhibitors (eg, ritonavir, saquinavir, indinavir, nelfinavir), antidepressants (eg, nefazodone, fluvoxamine, fluoxetine) and grapefruit juice may increase plasma levels of progestogens and result in undesirable efffects.

In a study investigating the effect of CYP3A4 inhibitors (ketoconazole, erythromycin) on the combination of estradiol valerate/Visannette-2, steady-state Visannette-2 plasma levels were increased. Co-administration with the strong inhibitor ketoconazole resulted in a 186% increase of AUC (0-24 hrs) at steady state for Visannette-2. When co-administered with the moderate inhibitor erythromycin, the AUC (0-24 hrs) of Visannette-2 at steady state were increased by 62%.

The clinical relevance of these interactions is unknown.

Effects of Visannette-2 on Other Drugs: Based on in vitro inhibition studies, a clinically relevant interaction of Visannette-2 with the cytochrome P-450 enzyme mediated metabolism of other drugs is unlikely.

Note: The prescribing information of concomitant medication should be consulted to identify potential interactions.

Drug-Food Interactions: A standardized high fat meal did not affect the bioavailability of Visannette-2.

Other Forms of Interactions: The use of progestogens may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins (eg, corticosteroid-binding globulin and lipid/lipoprotein fractions), parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.

Incompatibilities: Not applicable.


sponsored

References

  1. DailyMed. "DIENOGEST; ESTRADIOL VALERATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "46M3EV8HHE: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
  3. MeSH. "Hormone Antagonists". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Visannette-2 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Visannette-2. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


Consumer reported doses

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 18 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved